Podcasts about GSK

Mamileiros e mamiletes, vocês já abriram as suas plataformas de streaming favoritas e se depararam com uma inundação de indicações de conteúdo que contam como crimes reais aconteceram? Feminicídios, crimes em série, desaparecimentos e até mesmo assassinatos infantis são alguns dos variados temas abordados nessas histórias, que em sua maioria, bebem muito de um conteúdo jornalístico. A gente sabe que esse tipo de conteúdo não é novidade. Mas é inegável que o gênero true crime está cada vez mais popular no Brasil e no mundo. Recentemente, muitas pessoas se mobilizaram nas redes sociais para comentar sobre o assassinato da atriz Daniela Perez por conta da minissérie Pacto Brutal, da HBO Max. Outra produção que também gerou muitos comentários foi a série "Dahmer: Um Canibal Americano", da Netflix, que desde sua estreia já foi vista por mais de 190 milhões de pessoas Mas o que será o que buscamos ao assistir crimes cometidos há anos atrás enquanto ainda hoje esse tipo de crime continua sendo cometido cotidianamente? O crescimento dessas produções, em diferentes mídias, nos leva a questionar: estamos consumindo esse conteúdo para nos sentirmos mais alertas sobre os perigos do mundo ou consumir esses conteúdos nos faz acreditar que o mundo seja muito perigoso? No episódio, Cris Bartis e Ju Wallauer buscam entender o que existe por trás do fascínio por histórias de crimes reais? Para responder essa pergunta, elas conversam com Carol Moreira, uma das criadoras do podcast Modus Operandi e co-autora do livro Modus Operandi - guia de true crime, com Mabê Bonafé, a escritora Paula Febbe, que tem sete livros publicados que tratam da perversão e psicose, faz mestrado em Psicologia Criminal pela Universidad Europea Del Atlántico e apresenta podcasts de terror e true crime, e o sociólogo Wellington Lopes, educador e coordenador do Núcleo XI de Agosto de Educação, Cultura e Direitos Humanos da UNEafro Brasil. Vamos juntos! _____ FALE CONOSCO . Email: mamilos@b9.com.br _____ GSK Para diminuir a propagação de doenças no Brasil e no mundo, a imunização coletiva é essencial. É por isso que a GSK convidou o Mamilos para fazer esse programa esclarecedor sobre a meningite meningocócica, que é uma doença grave e que pode ser prevenida através da vacinação. De 2019 a 2022, foram mais de mil casos dessa doença aqui no Brasil. A meningite é uma doença séria que pode deixar sequelas para vida toda ou até mesmo causar a morte em até 24 horas. Além disso, é uma doença que pode afetar pessoas de todas as faixas etárias, incluindo bebês, crianças e adolescentes. A vacinação é a principal forma de prevenção contra a doença. Além de manter ambientes ventilados e limpos, evitar aglomerações e compartilhamento de objetos. Hoje, existem vacinas para a prevenção dos cinco principais sorogrupos que existem no Brasil: A, B, C, W e Y. A biofarmacêutica GSK é uma empresa global que pesquisa, desenvolve e fabrica vacinas e medicamentos especializados nas áreas de Doenças Infecciosas, HIV, Oncologia e Imunologia/Respiratória. Tem como propósito unir ciência, tecnologia e talento para vencer as doenças e impactar a saúde global. Informação e prevenção são sempre as melhores alternativas para um futuro com menos doenças, né, Cris? É isso. Converse com seu médico sobre as formas de prevenção contra a meningite e acesse o site juntos contra a meningite (juntoscontrameningite.com.br). _____ CASA FLORESTA Em setembro deste ano, o Instituto Socioambiental, o ISA, lançou a série “Casa Floresta” em formato podcast, para espalhar informação e a diversidade de vozes para o Brasil. Em seis episódios, o projeto leva convidados de diferentes partes do país a viver e refletir sobre as lutas e as belezas de povos indígenas, quilombolas e ribeirinhos em seus territórios. O objetivo é levar ao ouvinte experiências nas comunidades para provocar reflexões sobre a diversidade, economia, modos de vida, conhecimento ancestral e o pensamento de povos e comunidades tradicionais como inspiração para um futuro melhor. Nos episódios, os convidados visitam comunidades em territórios no Rio Negro, Xingu, Araguaia e Vale do Ribeira e convivem com as lutas e belezas de seus povos. Todos os episódios de 'Casa Floresta' já estão disponíveis nos tocadores Spotify, Apple Podcast, Deezer e Castbox. _____ CONTRIBUA COM O MAMILOS Quem apoia o Mamilos ajuda a manter o podcast no ar e ainda participa do nosso grupo especial no Telegram. É só R$9,90 por mês! Quem assina não abre mão. https://www.catarse.me/mamilos _____ Equipe Mamilos Mamilos é uma produção do B9 A apresentação é de Cris Bartis e Ju Wallauer. Pra ouvir todos episódios, assine nosso feed ou acesse mamilos.b9.com.br Quem coordenou essa produção foi a Beatriz Souza. Com a estrutura de pauta e roteiro escrito por Eduarda Esteves. A edição foi de Mariana Leão e as trilhas sonoras, de Angie Lopez. A capa é de Helô D'Angelo. A coordenação digital é feita por Agê Barros, Carolina Souza e Thallini Milena. O B9 tem direção executiva de Cris Bartis, Ju Wallauer e Carlos Merigo. O atendimento e negócios é feito por Rachel Casmala, Camila Mazza, Greyce Lidiane e Telma Zenaro.

Inspiring Stories 016 - Dr Natsuko Suwaki It can sometimes be hard to define the tangible outcomes you get from coaching. In this episode, I'm joined by Dr Natsuko Suwaki. In the last two years, since starting 1:1 coaching, Natsuko has made two big bold moves in her career at GSK. From the Global Labelling Delivery Manager to Operations Manager and more recently to Governance & Standards Director in Legal & Compliance. Join us is discovering how she has implemented the coaching insights and tools to become the person at work where just the right opportunities land on her lap. Being able to have the capacity to take on a big vision passion project in the EDI space and doing all of that while improving relationships and balance at home too. She is truly an inspiration. Subscribe to the Women In STEM Career & Confidence Podcast on your favourite platform and stay tuned. Resources: Join hundreds of Scientists and Professional Women in Breakthrough Unleashed on Facebook: https://www.facebook.com/groups/breakthroughunleashed/ Visit my Website: https://hannahnikeroberts.com/ Connect with me on LinkedIn: https://www.linkedin.com/in/hannahrobertscoaching/ Follow me on Twitter: https://twitter.com/HannahNikeR Follow me on Facebook: https://www.facebook.com/drhannahroberts Connect with me on Instagram: https://www.instagram.com/drhannahroberts/ Download Your FREE Guide: https://drhannahroberts.lpages.co/high-achievers-anxiety

Hi my friends! Hope you are having a wonderful day so far. Today on Murder, Mystery & Makeup, I wanted to talk about a highly requested story, the GSK aka EAR aka Original Night Stalker aka EARONS aka many more. I am currently reading the book I'll Be Gone In The Dark by Michelle McNamara  and wooooow weeee! Im not kidding, I have been having nightmares at night. This dude was just AWFUL. Truly truly the worst. Happy technology has come far and really hope that the victims were and are able to move forward and get some kind of closure. I could not imagine. If you are looking to learn more, I highly suggest reading Ill Be Gone In The Dark by Michelle McNamara !! Hope you have a wonderful rest of your week and you Make Good Choices xo Bailey Sarian Check out the original video here and don't forget to subscribe to my YouTube @BaileySarian! Tik Tok : https://bit.ly/3e3jL9v Instagram : http://bit.ly/2nbO4PR Facebook : http://bit.ly/2mdZtK6 Twitter : http://bit.ly/2yT4BLV Pinterest : http://bit.ly/2mVpXnY Youtube : http://bit.ly/1HGw3Og Snapchat : https://bit.ly/3cC0V9d Discord: https://discord.gg/BaileySarian

Mamileiros e mamiletes, vocês já ouviram aquele ditado, que diz assim: a alegria é maior quando partilhada? Hoje, a gente vai falar sobre um tema que atravessa muitas pessoas que estão nas redes sociais: afinal, estamos vivendo ou apenas produzindo conteúdo? A felicidade só vale se for compartilhada em nosso feed ou nos stories? Se viveu e não postou, não vale de nada? Aí é fila em confeitaria instagramável, em exposição instagramável, em show instagramável. É celular bloqueando a visão em momentos históricos e é sufoco se a bateria acaba no meio da festa. Afinal, se a gente não puder contar pra ninguém, se não restar testemunhos para posteridade, será que vivemos a experiência? Claro, a gente já fazia isso bem antes do celular, com os analógicos diários e álbuns de fotografia. Mas, agora, o "detalhe" que muda essa equação são os algoritmos. Que tornam as nossas experiências em um ranking, e através de incentivos sociais bem arquitetados, vão nos induzindo a expor cada vez mais, de formas cada vez mais elaboradas, nossas vidas. E essa é uma pressão que afeta não só quem vive de criar conteúdo para as redes, os famosos influenciadores digitais, mas também comerciantes e profissionais liberais, que dependem de divulgar seus serviços e produtos, de estabelecer uma clientela para tornar sua vida digital ativa. Afinal, a gente escolhe médico vendo o conteúdo que ele publica, nutricionista e até advogado. Nessa toada, será que todo mundo vai ter que ser produtor de conteúdo para conseguir se manter no mercado? Como a gente faz para separar o tempo que nos dedicamos para criar conteúdo online, dos momentos de desconexão, de esquecer dos outros? Como desconectar do wi-fi e conectar no agora, no instante, e viver plenamente a experiência que está acontecendo ao vivo? Para responder essas perguntas complexas, Cris Bartis e Ju Wallauer conversam com um trio que vai nos ajudar a encontrar algumas respostas. Participam do Mamilos de hoje Caco Bapt, publicitário, artista e um dos participantes do “Como Crescer - guia para lembrar de cuidar de si enquanto estiver tentando crescer na internet”, uma espécie de guia de sobrevivência para que pessoas que trabalham como criadoras de conteúdo e Juliana Costa, jornalista, doutoranda em Estudos de Mídia pela Universidade Federal do Rio Grande do Norte (UFRN) e pesquisadora de identidade e práticas jornalísticas, redes sociais digitais e teoria do jornalismo. Também integra o time de especialistas a jornalista Daniela Arrais, sócia-fundadora da Contente, um método de criação de conteúdo para uma vida com mais significado. Abre a mente, se desconecta um pouco e vem com a gente para essa reflexão! _____ FALE CONOSCO . Email: mamilos@b9.com.br _____ GSK Para diminuir a propagação de doenças no Brasil e no mundo, a imunização coletiva é essencial. É por isso que a GSK convidou o Mamilos para fazer esse programa esclarecedor sobre a meningite meningocócica, que é uma doença grave e que pode ser prevenida através da vacinação. De 2019 a 2022, foram mais de mil casos dessa doença aqui no Brasil. A meningite é uma doença séria que pode deixar sequelas para vida toda ou até mesmo causar a morte em até 24 horas. Além disso, é uma doença que pode afetar pessoas de todas as faixas etárias, incluindo bebês, crianças e adolescentes. A vacinação é a principal forma de prevenção contra a doença. Além de manter ambientes ventilados e limpos, evitar aglomerações e compartilhamento de objetos. Hoje, existem vacinas para a prevenção dos cinco principais sorogrupos que existem no Brasil: A, B, C, W e Y. A biofarmacêutica GSK é uma empresa global que pesquisa, desenvolve e fabrica vacinas e medicamentos especializados nas áreas de Doenças Infecciosas, HIV, Oncologia e Imunologia/Respiratória. Tem como propósito unir ciência, tecnologia e talento para vencer as doenças e impactar a saúde global. Informação e prevenção são sempre as melhores alternativas para um futuro com menos doenças. Converse com seu médico sobre as formas de prevenção contra a meningite e acesse o site juntos contra a meningite: http://www.juntoscontrameningite.com.br _____ CONTRIBUA COM O MAMILOS Quem apoia o Mamilos ajuda a manter o podcast no ar e ainda participa do nosso grupo especial no Telegram. É só R$9,90 por mês! Quem assina não abre mão. https://www.catarse.me/mamilos _____ Equipe Mamilos Mamilos é uma produção do B9 A apresentação é de Cris Bartis e Ju Wallauer. Pra ouvir todos episódios, assine nosso feed ou acesse mamilos.b9.com.br Quem coordenou essa produção foi a Beatriz Souza. Com a estrutura de pauta e roteiro escrito por Eduarda Esteves. A edição foi de Mariana Leão e as trilhas sonoras, de Angie Lopez. A capa é de Helô D'Angelo. A coordenação digital é feita por Agê Barros, Carolina Souza e Thallini Milena. O B9 tem direção executiva de Cris Bartis, Ju Wallauer e Carlos Merigo. O atendimento e negócios é feito por Rachel Casmala, Camila Mazza, Greyce Lidiane e Telma Zenaro.

After more than a year of respirator recalls, it's probably no surprise that Philips reported lower-than-expected revenues for the third quarter of this year. But that announcement also came with the revelation that the company is now laying off 4,000 workers and planning for even more restructuring. Fierce Medtech's Andrea Park discusses this latest news and digs into the long line of problems that led to this decision. Philips' downward slide started last June, with the recall of CPAP and BiPAP machines used to treat sleep apnea. As of this July, the FDA tallied 168 related deaths, and as of mid-October there were at least 342 pending class action cases against the company. Philips cuts 4,000 jobs, with more restructuring on the way, amid slipping sales and rising costs With FDA decision penciled in for May, GSK powers ahead in RSV race with Pfizer Johnson & Johnson doles out $16.6B to snatch up miniaturized heart pump maker Abiomed Thermo Fisher ties up $2.6B deal for cancer diagnostics maker The Binding Site Alkermes joins Bristol Myers in IL-2 exit with oncology business spinoff Pfizer boosts COVID vaccine projection to $34B on the back of strong Comirnaty haul See omnystudio.com/listener for privacy information.

Dr. Vamsi Velcheti and Dr. Benjamin Neel, of the NYU Langone Perlmutter Cancer Center, and Dr. John Heymach, of MD Anderson Cancer Center, discuss new therapeutic approaches for KRAS-mutant lung cancers and therapy options for RAS-altered tumors.   TRANSCRIPT Dr. Vamsidhar Velcheti: Hello, I'm Dr. Vamsidhar Velcheti, your guest host for the ASCO Daily News podcast today. I'm the medical director of the Thoracic Oncology Program at Perlmutter Cancer Center at NYU Langone Health. I'm delighted to welcome two internationally renowned physician-scientists, Dr. John Heymach, the chair of Thoracic-Head & Neck Medical Oncology at the MD Anderson Cancer Center, and my colleague, Dr. Benjamin Neel, the director of the Perlmutter Cancer Center at NYU Langone Health, and professor of Medicine at NYU Grossman School of Medicine. So, we'll be discussing new therapeutic approaches today for KRAS-mutant lung cancers, and we will talk about emerging new targeted therapy options for RAS-altered tumors. Our full disclosures are available in the show notes, and the disclosures of all the guests of the podcast can be found on our transcript at: asco.org/podcast. Dr. Heymach and Dr. Neel, it's such a great pleasure to have you here for the podcast today. Dr. John Heymach: My pleasure to be here. Dr. Benjamin Neel: Same here. Dr. Vamsidhar Velcheti: Dr. Neel, let's start off with you. As you know, RAS oncogenes were first discovered nearly four decades ago. Why is RAS such a challenging therapeutic target? Why has it taken so long to develop therapeutic options for these patients? Dr. Benjamin Neel: Well, I think a good analogy is the difference between kinase inhibitors and RAS inhibitors. So, kinase inhibitors basically took advantage of an ATP-binding pocket that's present in all kinases, but is different from kinase to kinase, and can be accessed by small molecule inhibitors. So, the standard approach that one would've thought of taking, would be to go after the GTP-binding pocket. The only problem is that the affinity for binding GTP by KRAS is three to four orders of magnitude higher. So, actually getting inhibitors that are GTP-binding inhibitors is pretty much very difficult. And then, until recently, it was felt that RAS was a very flat molecule and there weren't any surfaces that you could stick a small molecule inhibitor in. So, from a variety of biochemical and medicinal-pharmacological reasons, RAS was thought to be impervious to small molecule development. But as is often the case, a singular and seminal insight from a scientist, Kevan Shokat, really broke the field open, and now there's a whole host of new approaches to trying to drug RAS. Dr. Vamsidhar Velcheti: So, Dr. Neel, can you describe those recent advances in drug design that have enabled these noble new treatments for KRAS-targeted therapies? Dr. Benjamin Neel: So, it starts actually with the recognition that for many years, people were going after the wrong RAS. And by the wrong RAS, the overwhelming majority of the earlier studies on the structure, and for that matter, the function of RAS centered on HRAS or Harvey RAS. We just mutated in some cancers, most prominently, bladder cancer, and head & neck cancer, but not on KRAS, which is the really major player in terms of oncogenes in human cancer. So, first of all, we were studying the wrong RAS. The second thing is that we were sort of thinking that all RAS mutants were the same. And even from the earliest days, back in the late eighties, it was pretty clear that there were different biochemical properties in all different RAS mutants. But this sort of got lost in the cause and in the intervening time, and as a result, people thought all RASes were the same and they were just studying mainly G12V and G12D, which are more difficult to drug. And then, the third and most fundamental insight was the idea of trying to take advantage of a particular mutation in KRAS, which is present in a large fraction of lung cancer patients, which is, KRAS G12C. So, that's a mutation of glycine 12 to cysteine and Kevan's really seminal study was to use a library of covalently adducting drugs, and try to find ways to tether a small molecule in close enough so that it could hit the cysteine. And what was really surprising was when they actually found the earliest hits with this strategy, which was actually based on some early work by Jim Wells at Sunesis in the early part of this century, they found that it was actually occupying the G12C state or the inactive state of RAS. And this actually hearkens back to what I said earlier about all RASes being the same. And in fact, what's been recently re-appreciated is that some RAS mutants, most notably, G12C, although they're impervious to the gap which converts the active form into the inactive form, they still have a certain amount of intrinsic ability to convert from the inactive form. And so, they always cycle into the inactive form at some slow rate, and that allows them to be accessed by these small molecules in the so-called Switch-II Pocket, and that enables them to position a warhead close enough to the cysteine residue to make a covalent adduct and inactivate the protein irreversibly. Scientists at a large number of pharmaceutical companies and also academic labs began to understand how to access various other pockets in RAS, and also even new strategies, taking advantage of presenting molecules to RAS on a chaperone protein. So, there's now a whole host of strategies; you have a sort of an embarrassment of riches from an impoverished environment that we started with prior to 2012. Dr. Vamsidhar Velcheti: Thank you, Dr. Neel. So, Dr. Heymach, lung cancer has been a poster child for personalized therapy, and we've had like a lot of FDA-approved agents for several molecularly-defined subsets of lung cancer. How clinically impactful is a recent approval of Sotoracib for patients with metastatic lung cancer? Dr. John Heymach: Yeah. Well, I don't think it's an exaggeration to say this is the biggest advance for targeted therapies for lung cancer since the initial discovery of EGFR inhibitors. And let me talk about that in a little more detail. You know, the way that lung cancer therapy, like a lot of other cancer therapies, has advanced is by targeting specific driver oncogenes. And as Dr. Neel mentioned before, tyrosine kinases are a large percentage of those oncogenes and we've gotten very good at targeting tyrosine kinases developing inhibitors. They all sort of fit into the same ATP pocket, or at least the vast majority of them now. There are some variations on that idea now like allosteric inhibitors. And so, the field has just got better and better. And so, for lung cancer, the field evolved from EGFR to ALK, to ROS1 RET fusions, MEK, and so forth. What they all have in common is, they're all tyrosine kinases. But the biggest oncogene, and it's about twice as big as EGFR mutation, are KRAS mutations. And as you mentioned, this isn't a tyrosine kinase. We never had an inhibitor. And the first one to show that it's targetable, to have the first drug that does this, is really such an important breakthrough. Because once the big breakthrough and the concept is there, the pharmaceutical companies in the field can be really good at improving and modulating that. And that's exactly what we see. So, from that original insight that led to the design of the first G12C inhibitors, now there's dozens, literally dozens of G12C inhibitors and all these other inhibitors based on similar concepts. So, the first one now to go into the clinic and be FDA-approved is Sotoracib. So, this again, as you've heard, is inhibitor G12C, and it's what we call an irreversible inhibitor. So, it fits into this pocket, and it covalently links with G12C. So, when it's linked, it's linked, it's not coming off. Now, the study that led to its FDA approval was called the CodeBreak 100 study. And this was led in part, by my colleague Ferdinandos Skoulidis, and was published in The New England Journal in the past year. And, you know, there they studied 126 patients, and I'll keep just a brief summary, these were all refractory lung cancer patients. They either had first-line therapy, most had both chemo and immunotherapy. The primary endpoint was objective response rate. And for the study, the objective response rate was 37%, the progression-free survival was 6.8 months, the overall survival was 12.5 months. Now you might say, well, 37%, that's not as good as an EGFR inhibitor or the others. Well, this is a much harder thing to inhibit. And you have to remember in this setting, the standard of care was docetaxel chemotherapy. And docetaxel usually has a response rate of about 10 to 13%, progression-free survival of about 3 months. So, to more than double that with a targeted drug and have a longer PFS really is a major advance. But it's clear, we've got to improve on this and I think combinations are going to be incredibly important now. There's a huge number of combination regimens now in testing. Dr. Vamsidhar Velcheti: Thank you, Dr. Heymach. So, Dr. Neel, just following up on that, unlike other targeted therapies in lung cancer, like EGFR, ALK, ROS, and RET, the G12C inhibitors appear to have somewhat modest, I mean, though, certainly better than docetaxel that Dr. Heymach was just talking about; why is it so hard to have more effective inhibitor of KRAS here? Is it due to the complex nature of RAS-mutant tumors? Or is it our approach for targeting RAS? Is it a drug-related problem, or is it the disease? Dr. Benjamin Neel: Well, the short answer is I think that's a theoretical discussion at this point and there isn't really good data to tell you, but I suspect it's a combination of those things. We'll see with the new RAS(ON) inhibitors, which seem to have deeper responses, even in animal models, if those actually work better in the clinic, then we'll know at least part of it was that we weren't hitting RAS hard enough, at least with the single agents. But I also think that it's highly likely that since KRAS-mutant tumors are enriched in smokers, and smokers have lots of mutations, that they are much more complex tumours, and therefore there's many more ways for them to escape. Dr. Vamsidhar Velcheti: Dr. Heymach, you want to weigh in on that? Dr. John Heymach: Yeah, I think that's right. I guess a couple of different ways to view it is the problem that the current inhibitors are not inhibiting the target well enough, you know, in which case we say we get better and better inhibitors will inhibit it more effectively, or maybe we're inhibiting it, but we're not shutting down all the downstream pathways or the feedback pathways that get turned on in response, in which case the path forward is going to be better combinations. Right now, I think the jury is still out, but I think the data supports that we can do better with better inhibitors, there's room to grow. But it is also going to be really important hitting these compensatory pathways that get turned on. I think it's going to be both, and it seems like KRAS may turn on more compensatory pathways earlier than things like EGFR or ALK2, you know, and I think it's going to be a great scientific question to figure out why that is. Dr. Vamsidhar Velcheti: Right. And just following up on that, Dr. Heymach, so, what do we know so far about primary and acquired resistance to KRAS G12C inhibitors? Dr. John Heymach: Yeah. Well, it's a great question, and we're still very early in understanding this. And here, if we decide to call it primary resistance - meaning you never respond in the first place, and acquired - meaning you respond and then become resistant, we're not sure why some tumors do respond and don't respond initially. Now, it's been known for a long time, tumors differ in what we call their KRAS-dependence. And in cell lines and in mouse models, when you study this in the lab, there are some models where if you block KRAS, those cells will die immediately. They are fully dependent. And there's other ones that become sort of independent and they don't really seem to care if you turn down KRAS, they've sort of moved on to other things they're dependent on. One way this can happen is with undergoing EMT where the cell sort of changes its dependencies. And EMT is probably a reason some of these tumors are resistant, to start with. It may also matter what else is mutated along with KRAS, what we call the co-mutations, the additional mutations that occur along with it. For example, it seems like if this gene KEAP1 is mutated, tumors don't respond as well, to begin with. Now, acquired resistance is something we are gaining some experience with. I can say in the beginning, we all knew there'd be resistance, we were all waiting to see it, and what we were really hoping for was the case like with first-generation inhibitors with EGFR, where there was one dominant mechanism. In the first-generation EGFR, we had one mutation; T790M, that was more than half the resistance. And then we could develop drugs for that. But unfortunately, that's not the case. It looks like the resistance mechanisms are very diverse, and lots of different pathways can get turned on. So, for acquired resistance, you can have additional KRAS mutations, like you can have a KRAS G12D or V, or some other allele, or G13, I didn't even realize were commonly mutated, like H95 or Y96 can get mutated as well. So, we might be able to inhibit with better inhibitors. But the more pressing problem is what we call bypass; when these other pathways get turned on. And for bypass, we know that the tumor can turn on MET with MET amplification, NRAS, BRAF, MAP kinase, and we just see a wide variety. So, it's clear to us there isn't going to be a single easy to target solution like there was for EGFR. This is going to be a long-term problem, and we're going to have to work on a lot of different solutions and get smarter about what we're doing. Dr. Vamsidhar Velcheti: Yeah. Thank you very much, Dr. Heymach. And Dr. Neel, just following up on that, so, what do you think our strategies should be or should look like while targeting KRAS-mutant tumors? Like, do we focus on better ways to inhibit RAS, or do we focus on personalized combination approaches based on various alterations or other biomarkers? Dr. Benjamin Neel: Yeah. Well, I'd like to step back a second and be provocative, and say that we've been doing targeted therapies, so to speak, for a long time, and it's absolutely clear that targeted therapies never cure. And so, I think we should ask the bigger question, "Why is it that targeted therapies never cure?" And I would start to conceive of an answer to that question by asking which therapies do cure. And the therapies that we know do cure are immune therapies, or it's therapies that generate durable immune response against the tumor. And the other therapies that we know that are therapies in some cases against some tumors, and radiation therapy in some cases against some tumors. Probably the only way that those actually converge on the first mechanism I said that cures tumors, which is generating a durable immune response. And so, the only way, in my view, it is to durably cure an evolving disease, like a cancer, is to have an army that can fight an evolving disease. And the only army I know of is the immune system. So, I think ultimately, what we need to do is understand in detail, how all of these different mutations that lead to cancer affect immune response and create targetable lesions in the immune response, and then how the drugs we'd give affect that. So, in the big picture, the 50,000-foot picture, that what we really need to spend more attention on, is understanding how the drugs we give and the mutations that are there in the first place affect immune response against the tumor, and ultimately try to develop strategies that somehow pick up an immune response against the tumor. Now in the short run, I think there's also lots of combination strategies that we can think of, John, you know, alluded to some of them earlier. I mean one way for the G12C inhibitors, getting better occupancy of the drug, and also blocking this so-called phenomenon of adaptive resistance, where you derepress the expression of receptor tyrosine kinases, and their ligands, and therefore bypass through normal RAS or upregulate G12C into the GTP state more, that can be attacked by combining, for example, with the SHIP2 inhibitor or a SOS inhibitor. Again, the issue there will be therapeutic index. Can we achieve that with a reasonable therapeutic index? Also in some cases, like not so much in lung cancer, but in colon cancer, it appears as if a single dominant receptor tyrosine kinase pathway, the EGF receptor pathway, is often the mechanism of adaptive resistance to RAS inhibitors, and so, combining a RAS inhibitor with an EGF receptor inhibitor is a reasonable strategy. And then of course, some of the strategies they're already getting at, what I just mentioned before, which is to try to combine RAS inhibitors with checkpoint inhibitors. I think that's an expected and understandable approach, but I think we need to get a lot more sophisticated about the tumor microenvironment, and how that's affecting the immune response. And it's not just going to be, you know, in most cases combining with a checkpoint inhibitor. I think we ought to stop using the term immunotherapy to refer to checkpoint inhibitors. Checkpoint inhibitors are one type of immunotherapy. We don't refer to antibiotics when we mean penicillin. Dr. Vamsidhar Velcheti: Dr. Heymach, as you know, like, there's a lot of discussion about the role of KRAS G12C inhibitors in the frontline setting. Do you envision these drugs are going to be positioning themselves in the frontline setting as a combination, or like as a single agent? Are there like a subset of patients perhaps where you would consider like a single agent up front? Dr. John Heymach: So, I think there's no question G12C inhibitors are moving to the first-line question. And the question is just how you get there. Now, the simplest and most straightforward approach is to say, “Well, we'll take our standard and one standard might be immunotherapy alone, a PD-1 inhibitor alone, or chemo with the PD-1 inhibitor, and just take the G12C inhibitor and put it right on top.” And that's a classic strategy that's followed. That may not be that simple. It's not obvious that these drugs will always work well together or will be tolerated together. So, I think that's still being worked out. Now, an alternative strategy is you could say, “Well, let's get a foot in a door in the first-line setting by finding where chemotherapy and immunotherapy don't work well, and pick that little subgroup.” There are some studies there using STK11-mutant tumors, and they don't respond well to immunotherapy and chemotherapy and say, “Well, let's pick that first.” And that's another strategy, but that's not to get it for everybody in the first-line setting. That's just to pick a little subgroup. Or we may develop KRAS G12C inhibitor combinations by themselves that are so effective they can beat the standard. So, what I think is going to happen is a couple things; I think they'll first be some little niches where it gets in there first. I think eventually, we'll figure out how to combine them with chemotherapy and immunotherapy so it goes on top. And then I think over time, we'll eventually develop just more effective, targeted combos where we can phase out the chemo, where the chemo goes to the back of the line, and this goes to the front of the line. Dr. Vamsidhar Velcheti: And Dr. Heymach, any thoughts on the perioperative setting and the adjuvant/neoadjuvant setting, do you think there's any role for these inhibitors in the future? Dr. John Heymach: Yeah, this is a really exciting space right now. And so that makes this a really challenging question because of how quickly things are moving. I'll just briefly recap for everybody. Until recently, adjuvant therapy was just chemotherapy after you resected a lung cancer. That was it. And it provided about a 5% benefit in terms of five-year disease-free survival. Well, then we had adjuvant immunotherapy, like atezolizumab, approved, then we had neoadjuvant chemo plus immunotherapy approved; that's a CheckMate 816. And just recently, the AEGEAN study, which I'm involved with, was announced to be a positive study. That's neoadjuvant plus adjuvant chemo plus immunotherapy. So now, if you say, well, how are you going to bring a G12C inhibitor in there? Well, you can envision a few different ways; if you can combine with chemo and immunotherapy, you could bring it up front and bring it afterwards, or you could just tack it in on the back, either with immunotherapy or by itself, if you gave neoadjuvant chemo plus immunotherapy first, what we call the CheckMate 816 regimen. So, it could fit in a variety of ways. I'll just say neoadjuvant is more appealing because you can measure the response and see how well it's working, and we in fact have a neoadjuvant study going. But the long-term benefit may really come from keeping the drug going afterwards to suppress microscopic metastatic disease. And that's what I believe is going to happen. I think you're going to need to stay on these drugs for a long while to keep that microscopic disease down. Dr. Vamsidhar Velcheti: Dr. Neel, any thoughts on novel agents in development beyond KRAS G12C inhibitors? Are there any agents or combinations that you'd be excited about? Dr. Benjamin Neel: Well, I think that the YAP/TAZ pathway inhibitors, the TEAD inhibitors in particular, are potentially promising. I mean, it seems as if the MAP kinase pathway and the GAPT pathway act in parallel. There's been multiple phases which suggest that YAP/TAZ reactivation can be a mechanism of sort of state-switching resistance. And so, I think those inhibitors are different than the standard PI3 kinase pathway inhibitor, PI3 kinase mTOR inhibitor, rapamycin. I also think as we've alluded to a couple of times, the jury's still out in the clinic, of course, but it'll be very exciting to see how this new set of RAS inhibitors works. The sort of Pan-RAS inhibitors, especially the ones that hit the GTP ON state. So, the G12C inhibitors and the initial preclinical G12D inhibitors that have been recorded, they all work by targeting the inactive state of RAS, the RAS-GDP state. And so, they can only work on mutants that cycle, at least somewhat, and they also don't seem to be as potent as targeting the GTP or active state of RAS. And so, at least the Rev meds compounds, which basically use cyclophilin, they basically adapt the mechanism that cyclosporine uses to inhibit calcineurin. They basically use the same kind of a strategy and build new drugs then that bind cyclophilin and present the drug in a way that can inhibit multiple forms of RAS. So, it'll be interesting to see if they are much more efficacious in a clinic as they appear to be in the lab, whether they can be tolerated. So, I think those are things to look out for. Dr. Vamsidhar Velcheti: Dr. Heymach? Dr. John Heymach: Yeah, I agree with that. I'm excited to see that set of compounds coming along. One of the interesting observations is that when you inhibit one KRAS allele like G12C, you get these other KRAS alleles commonly popping up. And it's a little -- I just want to pause for a second to comment on this, because this is a little different than EGFR. If you inhibit a classic mutation, you don't get multiple other separate EGFR alleles popping up. You may get a secondary mutation in cyst on the same protein, but you don't get other alleles. So, this is a little different biology, but I think the frequency that we're seeing all these other KRAS alleles pop up tells us, I think we're going to need some pan-KRAS type strategy as a partner for targeting the primary driver. So for example, a G12C inhibitor plus a pan-KRAS strategy to head off these other alleles that can be popping up. So, I think that's going to be probably a minimum building block that you start putting other things around. And by partnering an allele-specific inhibitor where you might be able to inhibit it a little more potently and irreversibly with a pan-KRAS, you may solve some of these problems at the therapeutic window. You can imagine KRAS is so important for so many different cells in your body that if you potently inhibit all KRAS in your body, bad things are likely to happen somewhere. But if you can potently inhibit the mutant allele and then dampen the other KRAS signaling that's popping up, it's more hopeful. Dr. Benjamin Neel: There is a mouse model study from Mariano Barbacid's lab, which suggests that postnatal, KRAS at least, complete inhibition is doable. So, you could take out KRAS postnatally and the mice are okay. Whether that translates to human of course, is not at all clear. And you still have the other RAS alleles, the HRAS, the NRAS that you'd still have to contend with. Dr. John Heymach: Yeah, it's an interesting lesson. We've shied away from a lot of targets we thought weren't feasible. I did a lot of my training with Judah Folkman who pioneered targeting angiogenesis. And I remember hearing this idea of blocking new blood vessels. I said, "Well, everyone is just going to have a heart attack and die." And it turns out you can do it. You have to do it carefully, and in the right way but you can separate malignant or oncogenic signaling from normal signaling in an adult, pretty reasonably in a lot of cases where you don't think you could. Dr. Vamsidhar Velcheti: All right. So, Dr. Neel, and Dr. Heymach, any final closing comments on the field of RAS-targeted therapies, you know, what can we hope for? What can patients hope for, let's say five years from now, what are we looking at? Dr. John Heymach: Well, I'll give my thoughts I guess first, from a clinical perspective, I think we're already seeing the outlines of an absolute explosion in targeting KRAS over the next five years. And I think there's a really good likelihood that this is going to be the major place where we see progress, at least in lung cancer, over these next five years. It's an example of a problem that just seemed insolvable for so long, and here I really want to acknowledge the sustained support for clinical research and laboratory research focused around RAS. You know, the NCI had specific RAS initiatives and we've had big team grants for KRAS, and it shows you it's worth these large-scale efforts because you never know when that breakthrough is going to happen. But sometimes it just takes, you know, opening that door a little bit and everybody can start rushing through. Well, I think for KRAS, the door has been opened and everybody is rushing through at a frantic rate right now. So, it's really exciting, and stay tuned. I think the landscape of RAS-targeting is going to look completely different five years from now. Dr. Benjamin Neel: So, I agree that the landscape will definitely look different five years from now, because it's reflective of stuff that's been in process for the last five years. And it takes about that long to come through. I want to make two comments; one of which is to slightly disagree with my friend, John, about these big initiatives. And I would point out that this RAS breakthrough did not come from a big initiative, it came from one scientist thinking about a problem uniquely in a different way. We need a basic science breakthrough, it almost always comes from a single lab person, thinking about a problem, often in isolation, in his own group. What big initiatives can help with is engineering problems. Once you've opened the door, and you want to know what the best way is to get around the house, then maybe big initiatives help. But I do think that there's been too much focus on the big team initiative and not enough on the individual scientists who often promote the breakthrough. And then in terms of where I see the field going, what I'd really like to see, and I think in some pharmaceutical companies and biotechs, you're seeing this now, and also in academia, but maybe not enough, is that sort of breaking down of the silos between immunotherapy and targeting therapy. Because I agree with what John said, is that targeted therapy, is just sophisticated debulking. If we want to really make progress-- and on the other hand, immunotherapy people don't seem to, you know, often recognize that these oncogenic mutations in the tumor actually affect the immune system. So, I think what we need is a unification of these two semi-disparate areas of therapeutics in a more fulsome haul and that will advance things much quicker. Dr. Vamsidhar Velcheti: Thank you both, Dr. Neel and Dr. Heymach, for sharing all your valuable insights with us today on the ASCO Daily News podcast. We really appreciate it. Thank you so much. Dr. John Heymach: Thanks for asking us. Dr. Benjamin Neel: It's been great having us. Dr. Vamsidhar Velcheti: And thank you all to our listeners, and thanks for joining us today. If you value our insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review and subscribe. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Vamsi Velcheti @VamsiVelcheti Dr. Benjamin Neel @DrBenNeel Dr. John Heymach Want more related content? Listen to our podcast on novel therapies in lung cancer.    Advances in Lung Cancer at ASCO 2022 Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Vamsi Velcheti: Honoraria: Honoraria Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline Dr. Benjamin Neel: None disclosed Dr. John Heymach: None disclosed    

APAC stocks were mixed with the region cautious after the lacklustre handover from the US ahead of the FOMCDXY slightly softened after the choppy performance yesterday, EUR/USD traded marginally higher, USD/JPY retreated overnightNorth Korea reportedly fired at least 10 missiles from the east and west coasts; South Korea launched air-to-ground missiles which were fired towards the north of the maritime borderChina locked down the area around the world's largest iPhone factory, according to BloombergLooking ahead, highlights include German Unemployment, EZ Manufacturing PMI (Final), Australian Services & Composite PMI (Final), FOMC Policy Announcement & Press Conference, Germany Supply, earnings from GSK, Maersk, Osram, Vestas Wind & QualcommClick here for the Week Ahead previewRead the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Mamileiros e mamiletes, o programa de hoje é sobre qual é o limite da privacidade. Será que o entendimento do que é público e do que é privado mudou muito ao longo dos anos? Você já parou para pensar como a ideia do que é privacidade se transformou com o passar do tempo? Com as redes sociais e com uma sociedade cada vez mais conectada, a autoexposição se naturalizou bastante, uma vez que se tornou comum mostrar a vida privada no espaço público e ter como prêmio a visibilidade. Mas a sensação que dá é que a gente teve uma mudança muito rápida no que é comum mostrar para o outro. Quantas vezes você já viu alguém publicar algo na internet e teve a sensação de que aquilo merecia um tratamento privado? Antes, o que a gente mantinha só pra gente, dividia com amigos mais próximos ou até com a família, hoje tornou-se tornou comum dividir com o mundo inteiro, é como se a nossa máscara pública mudasse muito rápido e o borramento entre as fronteiras do público e do privado fosse cada vez maior. E essa mudança parece ser muito geracional, afinal, os limites de privacidade parecem mudar de acordo com cada geração. No caso de pais adolescentes, por exemplo, a impressão que dá é que se a gente não se atualizar um pouco sobre o que significam essas modificações, não dá acompanhar essa geração ao ponto de exercitar os novos códigos. Qual a régua que divide o público do privado nas redes sociais? Quais são os códigos de hoje e o que se tornou comum? Como lidar com uma geração que ao mesmo tempo que celebra a exibição de si, reivindica o direito à privacidade? Para responder essas perguntas complexas, Cris Bartis e Ju Wallauer conversam hoje com a escritora e jornalista Pollyana Ferrari, pesquisadora em Comunicação Digital, com pós-doutorado em Comunicação pela Universidade Beira Interior (UBI), de Portugal, e professora do programa Tecnologias da Inteligência e Design Digital da PUC-SP, e com o psicanalista Pedro de Santi, professor da ESPM, com especializações em teoria psicanalítica e em cultura material e consumo. Vamos juntos! _____ FALE CONOSCO . Email: mamilos@b9.com.br _____ GSK Para diminuir a propagação de doenças no Brasil e no mundo, a imunização coletiva é essencial. É por isso que a GSK convidou o Mamilos para fazer esse programa esclarecedor sobre a meningite meningocócica, que é uma doença grave e que pode ser prevenida através da vacinação. De 2019 a 2022, foram mais de mil casos dessa doença aqui no Brasil. A meningite é uma doença séria que pode deixar sequelas para vida toda ou até mesmo causar a morte em até 24 horas. Além disso, é uma doença que pode afetar pessoas de todas as faixas etárias, incluindo bebês, crianças e adolescentes. A vacinação é a principal forma de prevenção contra a doença. Além de manter ambientes ventilados e limpos, evitar aglomerações e compartilhamento de objetos. Hoje, existem vacinas para a prevenção dos cinco principais sorogrupos que existem no Brasil: A, B, C, W e Y. A biofarmacêutica GSK é uma empresa global que pesquisa, desenvolve e fabrica vacinas e medicamentos especializados nas áreas de Doenças Infecciosas, HIV, Oncologia e Imunologia/Respiratória. Tem como propósito unir ciência, tecnologia e talento para vencer as doenças e impactar a saúde global. Informação e prevenção são sempre as melhores alternativas para um futuro com menos doenças, né, Cris? É isso. Converse com seu médico sobre as formas de prevenção contra a meningite e acesse o site juntos contra a meningite. _____ CONTRIBUA COM O MAMILOS Quem apoia o Mamilos ajuda a manter o podcast no ar e ainda participa do nosso grupo especial no Telegram. É só R$9,90 por mês! Quem assina não abre mão. https://www.catarse.me/mamilos _____ Equipe Mamilos Mamilos é uma produção do B9 A apresentação é de Cris Bartis e Ju Wallauer. Pra ouvir todos episódios, assine nosso feed ou acesse mamilos.b9.com.br Quem coordenou essa produção foi a Beatriz Souza. Com a estrutura de pauta e roteiro escrito por Eduarda Esteves. A edição foi de Mariana Leão e as trilhas sonoras, de Angie Lopez. A capa é de Helô D'Angelo. A coordenação digital é feita por Agê Barros, Carolina Souza e Thallini Milena. O B9 tem direção executiva de Cris Bartis, Ju Wallauer e Carlos Merigo. O atendimento e negócios é feito por Rachel Casmala, Camila Mazza, Greyce Lidiane e Telma Zenaro.

O herpes-zóster é uma doença infecciosa causada por um vírus, o varicela-zóster, o mesmo que é responsável pela catapora. Ele que permanece no organismo de quem teve a doença e pode ‘despertar' em qualquer fase da vida, principalmente em momentos em que ocorre uma queda expressiva na imunidade. A boa notícia é que o herpes-zóster pode ser prevenido por vacinação. Para entender mais essa doença, seus sinais e sintomas, ouça o podcast produzido pelo Estadão Blue Studio com o patrocínio da GSK.See omnystudio.com/listener for privacy information.

Synopsis: Stanley Crooke is Founder and CEO of n-Lorem Foundation, a nonprofit with the goal of discovering, developing and providing experimental ASO treatments to nano-rare patients for free for life. He joins us for a discussion about the business model behind rare diseases and how n-Lorem is looking to industrialize and scale the treatment of this unique population. Stanley talks about the challenges behind developing and bringing a new modality to the clinic, the company's collaboration with the FDA, and how n-Lorem seeks to be sustainable and scalable over time. Biography: Dr. Crooke is the founder, chairman and chief executive officer of n-Lorem, a nonprofit foundation focused on providing treatments for patients with nano-rare disease (1 to 30 patients worldwide), which he initiated in January 2020. Prior to n- Lorem, Dr. Crooke founded and was Chairman and Chief Executive Officer and Lead Scientist of Ionis Pharmaceuticals. During his tenure at Ionis, he led the scientific development of a new platform for drug discovery, antisense technology and the creation of one of the largest and more advanced development pipelines in the biotechnology industry, and commercialized several antisense drugs including, Spinraza, Tegsedi and others. Early in Dr. Crooke's career, he led the creation of the first broad anticancer program in the industry at Bristol-Myers, bringing numerous anticancer drugs to the market in the first five years of his career. He then assumed responsibility for worldwide R&D (president) at SmithKline Beckman (now GSK). During his tenure at SKB, Dr. Crooke led the restructuring of R&D and the development of several drugs that were commercialized. Dr. Crooke has also contemporaneously led a successful academic career becoming a full professor at Baylor College of Medicine and the University of Pennsylvania Medical School where he trained a number of PhD students and won several teaching awards. Dr. Crooke has been an active scientist throughout his career as well. Dr. Crooke has received a number of awards, most recently, Prix Galein Roy Vagellos Pro Bono Humanum Award, the American Chemical Society's E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Lifetime Achievement Award presented by the Oligonucleotide Therapeutics Society, the Scrip Lifetime Achievement Award and the 2019 Massry Prize. Dr. Crooke received his M.D. and Ph.D. degrees and house staff training at Baylor College of Medicine and has been an active scientist throughout his career. In 2021, Dr. Crooke has been named Distinguished Alumnus of both Baylor College of Medicine's Graduate and Medical schools and named one of the 20 of the most influential biopharma R&D executives by Endpoints News. He has published nearly 600 scientific publications, edited more than 20 books, has numerous patents, and led the development of more than 23 drugs that have been commercialized.

D We have a fantastic lady for you on the show today! Christina Foxwell is here to tell her powerful story of her healing journey from domestic violence. She is talking about her new book, Glass Angel as well. Join me for a delightful conversation Down Under! Transcript below! Biography I am a HUMAN one who is passionate about People and the impact they have in their own life and their world. I believe we are better together and through my work as a Transformation and Performance Coach I get to see people be better, align and find joy and unlock their full potential.I am one who believes that LOVE matters and that we are wired to survive. So It's time we start looking at our world from a place of deeper connection, this only happens when I can shift the source that feeds me and impact my world for the better. Imagine if we could have workplaces where people are kinder, open and willing to bring what they have. Where we can be honest, open and recognise that the change we want in our world starts with how we see it and inside each of us. Grow me is your choice - it belongs to youLead others is your calling to be with others and allow their growth while you support, learn and connect deeplyBe better together is a place where we can learn from each other, align, connect deeply, work through our mutual problems and choose to commit to our success and the heart of our work. I have run a successful practice in Sydney Australia for the last 10 years. I am a speaker, author, coach, consultant and a human helping others be better together. I am about to publish my four book called: The Glass Angel: A guide to freedom, peace, transformation and growth. Unlocking your Potential. The Glass Angel aims to help people break free of the barriers they've put up in their lives, leading them gently towards overcoming shame, while also learning the importance of forgiveness and letting go of the past. Growth and learning about who we are, how we can be our BEST SELF, who we already are.... Finally some of my customers are and have been:Australia Post, UGL, PHN Networks, Abbott, News Corp, Zoetis, GSK, Church and Dwight, Clorox, Heavy Vehicle Regulatory Authority, BFG, Woolworths, BUPA, Smith and Nephew, Greater Group, Media Super, Panalpina, City of Paramatta Council, Sedgman, Seek, Baycorp (Across Asia), Novartis, Sydney Water, Life Screen, Adora Fertility, Tobia Partners, Ventia, Veolia, Cushman and Wakefield, Ecomist.... and so many more. https://www.ignitepurpose.com.au/product/the-glass-angel The Glass Angel: A guide to freedom, peace, transformation and growth. Unlocking your Potential Website: https://dswministries.org Email: diana@dswministries.org Social media links: Facebook: https://www.facebook.com/DSW-Ministries-230135337033879 Twitter: https://twitter.com/DswMinistries YouTube: https://www.youtube.com/channel/UCxgIpWVQCmjqog0PMK4khDw/playlists Instagram: https://www.instagram.com/dswministries/ https://dswministries.org/subscribe-to-podcast/ Available on Apple Podcasts, Spotify, iHeart Radio, Google Podcasts, Pandora, Stitcher, Listen Notes Keep in touch with me! Email subscribe to get my handpicked list of the best resources for abuse survivors! https://thoughtful-composer-4268.ck.page #abuse #trauma Mentoring https://youtu.be/WWgkERpkIoY An easy way to help my ministry: https://dswministries.org/product/buy-me-a-cup-of-tea/ A donation link: https://dswministries.org/donate/ Affiliate links: Can't travel to The Holy Land right now? The next best thing is Walking The Bible Lands! Get a free video sample of the Bible lands here! https://www.walkingthebiblelands.com/a/18410/hN8u6LQP Get one free month of Blubrry podcast hosting with the promotional code: FAITHFUL http://create.blubrry.com/resources/podcast-media-hosting/?code=FAITHFUL Get quality podcast guests and interviews from PodMatch!

The CPG Guys, PVSB and Sri are joined in this episode by Rachel Marler, Chief Customer Officer of Haleon, the newly rebranded spinoff from GSK Consumer Healthcare.  Haleon plc is a British multinational consumer healthcare company. It is the largest consumer healthcare business in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins.Follow Rachel Marler on LinkedIn at:  https://www.linkedin.com/in/rachel-marler-rkm/Follow Haleon LinkedIn at: https://www.linkedin.com/company/haleon/Follow Haleon online at: http://haleon.comRachel answers these questions:1) Your story starts at U. Penn Wharton, and you've been at brands such as P&G, Walmart, Tyson foods. Then GSK and Haleon. Give us the scoop - how did all this play out and what is your driver for being here at Haleon in this role?2) Why this change from GSK to Haleon now? Take us through how separating from GSK Pharma is  beneficial to consumers and retailers today including your go-to market model?3) How does your separation to Haleon change your strategy for digital commerce? 4) What does your team specifically focus on - is it strategy or execution? How are you focused on evolving your team?5) How do you partner on the Omnichannel mission with your customers  and those that are not on your team?   6) What are you personally most excited about in joining Haleon? 7) What are some key learnings from the last 2 years you would share with our audience they should focus on? 8) One last question on the store - what is the role of the store in strategic planning in today's environment? Is the planogram still gold in your categories?CPG Guys Website: http://CPGGuys.comFMCG Guys Website: http://fmcgguys.comCPG Scoop. Website: http://CPGscoop.comDISCLAIMER: The content in this podcast episode is provided for general informational purposes only. By listening to our episode, you understand that no information contained in this episode should be construed as advice from CPGGUYS, LLC or the individual author, hosts, or guests, nor is it intended to be a substitute for research on any subject matter. Reference to any specific product or entity does not constitute an endorsement or recommendation by CPGGUYS, LLC. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.  CPGGUYS LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual's use of, reference to, or inability to use this podcast or the information we presented in this podcast.

Perry McLean, Head of Operational Excellence at GSK, talks about GSK's new Canadian headquarters, embracing a hybrid working model, and the importance of emotional intelligence in the digital workplace. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit healthbiz.substack.com

In this week's episode Helena and Isabel were honoured to be joined by Rino Rappuoli, Head of External R&D and Chief Scientist at GSK Vaccines. He discusses his career inspiration and journey; his work on novel scientific concepts such as reverse vaccinology, which modern vaccines are based on; and his interest in meningitis, as well as the lasting impact of COVID-19 on the vaccine landscape, how he sees the field developing in future and what investment and innovation is needed from pharma to achieve his vision.  If you're interested in learning more about the topic areas discussed in this episode, check out the following content:  Keeping the spark alive in vaccine development https://www.emg-gold.com/post/keeping-the-spark-alive-in-vaccine-development  GSK's Judy Stewart on vaccines https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases   The return of the vaccines https://www.emg-gold.com/post/the-return-of-the-vaccines  Is mRNA the future of vaccine technology? https://www.emg-gold.com/_files/ugd/b8a9db_63ca75dce7a64cd39b356ac1ffb18358.pdf 

Dr. Robert Hollingsworth is the current Chief Scientific Officer of Shoreline Biosciences, a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)- utilizing its proprietary platforms. Dr. Hollingsworth joins Shoreline from Pfizer, where he served as Chief Scientific Officer and Vice President of Cancer Vaccines and Immunotherapeutics. Prior to Pfizer, he was Senior Director of Oncology Research at MedImmune where he led and advanced a large portfolio of more than twenty programs, including CAR-T programs, and contributed to the approval of durvalumab.  Before that, he held several R&D positions at GSK, Pharmacia, and Upjohn.In this episode, we discuss Robert's long career in biopharma, the platform technology being developed at Shoreline, and the role of strategic partnerships in early-stage development.Hosted by Gustavo Carrizo and Joe Varriale.

Our archers pick up their bows and arrows and take aim at this week's stories. Only on the PlayingFTSE show! Steve and Steve are in this week to talk about stories. And they're starting with the small stuff. It's the UK's latest economic plan. This has been top of mind for Steve W for a few days now and he's been trying to figure his way around it. He's not a fan, but he thinks it's been badly covered in the mainstream media. What does it mean for the Steves and UK citizens and UK investors? Neither has an answer, but they'll do their best to try and work through things. It's unusual that we get ourselves involved in anything political and so the rest of the show is stocks, stocks, and more stocks. We've got SIX that are on our radar as we head into October and Q4. First up, Steve D is looking at Kering. He's nearly always looking at Kering, because of all the designer gear he frequently wears. But he thinks the shares are particularly eye-catching at the moment. Find out why as Steve takes us through the stock's latest decline. Second, Steve W is looking at Rightmove. He's nearly always looking at Rightmove, because of his enormous property empire. But he thinks that the shares are particularly eye-catching at the moment. Find out why as Steve takes us through the stock's latest decline. Third, Steve D is watching Legal & General. The UK insurer stands to do well as interest rates rise and the stock has come down to a level where Steve thinks it pays an interesting dividend. Could this be enough to get him over the line? Fourth, Steve W is watching Wells Fargo. The US bank stands to do well as interest rates rise and the stock has come down to a level where Steve thinks it pays an interesting dividend. Could this be enough to get him over the line? Fifth, Steve D has his eye on some healthcare. This is one we haven't talked about much on the show, but Steve is looking at Biomerieux. Steve doesn't back himself to evaluate a pharmaceutical's pipeline, but his thesis here doesn't depend on this. So what's he seeing here? Sixth, Steve W has his eye on some healthcare. This is one we haven't talked about much on the show, but Steve is looking at GSK. Steve doesn't back himself to evaluate a pharmaceutical's pipeline, but his thesis doesn't depend on this. So what's he seeing here? All on this week's PlayingFTSE Podcast!

Kate Nash OBE is creator & CEO of PurpleSpace (www.purplespace.org). Established in 2015 it is the world's only leadership development membership hub for disability employee resource groups [ERG] / networks.PurpleSpace delivers leadership know-how to disability employee resource group leaders who want to accelerate the pace of cultural change for employees with disabilities. The global community now stands at 2,000+ leaders across 200 organisations who together employ 1 million employees with disabilities. The community was born by demand following the publication of her first book ‘Secrets & Big News' in 2014: https://www.purplespace.org/home?myhub&selected=530.PurpleSpace leads the #PurpleLightUp – a worldwide global movement to celebrate the economic contribution of disabled employees and drive inclusive work practices – as part of the UN International Day of Persons with Disabilities on 3rd December each year. In 2021, the movement reached 253 million connections with content viewed over 186 thousand times.She is External Advisor to GSK's Global Disability Council, Strategic Disability Advisor to Post Office Ltd and a member of the UK Government's Minister's Disability Confidence Business Leaders' Group.In 2007 she was awarded an OBE for services to disabled people.Her second book ‘Positively Purple' is published on 3rd October 2022 by Kogan Page.

Het is chaos in het Verenigd Koninkrijk. De nieuwe Britse premier Liz Truss neemt een ongekende gok met de economie: ze verlaagt de belasting voor rijken en bedrijven. Maar investeerders schrikken van de plannen. Het pond daalde tot een historisch dieptepunt. Tegelijkertijd stijgt de rente op Britse staatsobligaties. De Bank of England drukt de paniekknop in. En zelfs het Internationaal Monetair Fonds tikt de Britse regering deze week op de vingers.  Waarom blijft Liz Truss zo vasthouden aan haar omstreden plannen? En wat betekent dit uiteindelijk voor jou als belegger? Je hoort het van Nico Inberg (De Aandeelhouder). Verder:  De topman van Unilever gaat met pensioen. Europa is in paniek door de aanvallen op de Nord Stream-gaspijpleidingen    See omnystudio.com/listener for privacy information.

[Yesterday 15:46] Helena Beer Top tips for digital innovation and the future of patient centricity In this week's episode of The GOLD Podcast, Helena is joined by Konrad Dobschuetz, National Director at NHS Innovation Accelerator and Chief Enterprise Officer at UCL Partners, who discusses all things digital innovation. They chat about his transition from the fashion industry to pharma, some digital innovation top tips for companies and his new role at the NHS and the importance of collaboration, plus his take on how the humble automobile may someday turn into a diagnostic tool. And in ‘news you might have missed', Helena discusses the latest from Boehringer Ingelheim, Sanofi and GSK. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Meet GOLD's catalyst - digital innovator, Davidek Herron: https://www.emg-gold.com/post/podcast-catalyst-digital-innovator-davidek-herron Digitalisation: moving past paperless: https://www.emg-gold.com/post/digitalisation-moving-past-paperless Reframing pharma's bad boy reputation https://www.emg-gold.com/post/reframing-pharma-s-bad-boy-reputation Taking a bet on blockchain https://www.emg-gold.com/post/taking-a-bet-on-blockchain

The CEO of GSK (formerly GlaxoSmithKline), Dame Emma Walmsley, joins hosts Omar Abbosh and will.i.am to discuss how innovation and biotechnology are changing the future of medicine. GSK has a history of discovering game-changing medical therapies, from pharmaceuticals to consumer healthcare products. Now the global company is spinning off its consumer product business into an independent company, allowing GSK to focus fully on drug development and vaccines.

Two Big Pharma companies, GSK and Takeda, made moves this week to bolster their environmental sustainability efforts. GSK is focusing on its supply chain and Takeda on its electrical sources in the U.S. In GSK's case, the development is part of a larger trend of companies focusing on emissions from outside of their direct operations. Fierce's Fraiser Kansteiner and Eric Sagonowsky will discuss what we can expect on environmental sustainability at Big Pharmas. To learn more about topics in this episode:  GSK puts suppliers on the hook as it amps up sustainability crusade  A $3M gene therapy: Bluebird bio breaks its own pricing record with FDA approval of Skysona Merck finally gets FDA nod to relaunch HIV trials, but drops preventive therapy plans FDA plans advisory committee meeting to discuss racial bias built into pulse oximeters Smartphone cameras could replace pulse oximeters to measure blood oxygen at home: study Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Wie wird das Leben nach dem Krebs? Dr. med. Woppen gibt einen Einblick in die Langzeitfolgen von Krebs. Viele Krebserkrankungen sind heute bereits heilbar und das Leben nach dem Krebs rückt immer mehr in den Fokus. Was heißt eigentlich überhaupt überleben bei einer Krebserkrankung? wenn ich länger als fünf Jahre ohne wiederkehrende Erkrankung lebe, dass ich dann davon geheilt bin? Wie erkennt man denn dann das Rezidiv und wie sieht die Nachsorge aus beim Gebärmutterkörperkrebs?GICG: https://gcigtrials.org/Studien Portal: www.studienportal-gyn.deWebseite: https://www.krebs-podcast.deSprechstunde Langzeitüberlebende: https://survivorship-clinic.de/ Referenten:Dr. med. Hannah Woopen, MSc (Fachärztin, Charité – Universitätsmedizin Berlin, Schwerpunkt: Langzeitüberleben bei Patientinnen mit Ovarialkarzinom (Studienleiterin "Carolin meets HANNA"), Junior Clinical Scientist, Master of Science - Clinical Research)Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin) Erfahren Sie in dieser von vier Folgen alles zum Thema Leben mit dem Krebs. Erste Folgen zu der Serie Endometrium Karzinom: Folge 13-15. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten.Die meisten Patienten mit Endometriumkarzinom überleben zehn Jahre, aber die Krebserkrankung ist nicht der einzige Faktor, der berücksichtigt werden muss. Nach fünf Jahren sollten keine Rezidive mehr auftreten, aber es kann vorkommen, dass nach fünf, zehn oder sogar fünfzehn Jahren doch ein Rezidiv auftritt.Die GSIG hat sich darauf geeinigt, dass Langzeitüberleben mit gynäkologischen Tumoren als Überleben von mindestens fünf Jahren gilt.Die meisten Frauen mit Endometriumkarzinom sterben nicht an Krebs, sondern an Herzkrankheiten. Es ist wichtig, dass Sie Ihre Gesundheitskompetenz stärken, um zu verhindern, dass Sie erneut an Krebs erkranken. Man sollte sich von einem Expertenteam behandeln lassen und sich auch eine zweite Meinung einholen, wenn man an Krebs erkrankt ist.Die neuen Medikamente zur Immuntherapie von Krebs werden wahrscheinlich einen großen Einfluss auf die Prognose haben, aber die Langzeitnebenwirkungen sind noch nicht bekannt.Viele Frauen, die wegen Endometriumkrebs behandelt wurden, haben Probleme mit der sexuellen Funktion, was die Lebensqualität erheblich beeinträchtigen kann. Auch Osteoporose ist eine häufige Nebenwirkung der Krebsbehandlung.Die Deutsche Krebsgesellschaft hat Verzeichnisse von Zentren, an die man sich wenden kann, und der Langzeitüberlebendenschwerpunkt in der Survivorship Klinik in Berlin ist empfehlenswert.#fernmetastasen #rezidiv #ASCO #GICG #survivorship #cancersurvivor Hosted on Acast. See acast.com/privacy for more information.

As medications get more specialized, so has the need for better engagement to help patients with their prescriptions. Manufacturers are investing in tools and programs that can help patients on their medication journeys, and digital strategies are front and center. In this episode, Greg Kefer is joined by Emily Gibb, who leads the patient service organization at GSK, a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. In this wide-ranging discussion, Emily shares her thoughts about innovation and how modern, mobile technology is maturing and lowering barriers for patients. Ultimately, the goal is to provide a digital experience that is simple and natural, so patients can get the answers and support they need to stay healthy.

As medications get more specialized, so has the need for better engagement to help patients with their prescriptions. Manufacturers are investing in tools and programs that can help patients on their medication journeys, and digital strategies are front and center. In this episode, Greg Kefer is joined by Emily Gibb, who leads the patient service organization at GSK, a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. In this wide-ranging discussion, Emily shares her thoughts about innovation and how modern, mobile technology is maturing and lowering barriers for patients. Ultimately, the goal is to provide a digital experience that is simple and natural, so patients can get the answers and support they need to stay healthy.

The number of women and people with gynae organs raising ‘red flag' gynaecological concerns with their GP has reduced by almost a fifth since before the COVID-19 pandemic, according to new data1. Each year, more than 22,000 people are diagnosed with one of the five gynaecological cancers – womb, ovarian, cervical, vulval, and vaginal – with 12 dying from these conditions each day2. LPD electronic medical record data shows an 18% decrease in patients reporting abnormal gynaecological bleeding since before the COVID-19 pandemic1. This trend is also seen with patients reporting pain, lumps, or irritation (including on the vulva, vagina and labia), with a 12% decrease in patients reporting these symptoms since before the pandemic1. That's why GSK, in partnership with The Eve Appeal, is launching ‘Be Gynae Aware' – a new campaign to raise awareness of gynaecological health to help people understand what is normal for them, and to feel confident visiting their doctor for advice if they have any concerns. Furthermore, as research shows one in four have not felt listened to in a gynae health appointment3, two discussion guides have been created – one for patients and one for healthcare professionals. General Practitioner, Dr Hilary Jones MBE, believes no topic should be off-limits, regardless of the gender of the GP you are speaking to. Hosted on Acast. See acast.com/privacy for more information.

Communication is 7% Words 38% Tone of Voice 55% Body Language   Jason A. Duprat, Entrepreneur, Healthcare Practitioner, and Host of the Healthcare Entrepreneur Academy podcast, sits down with Shelly O'Donovan, CEO of Authentic Influence Group with certifications in Body Language Training and the Big 5 Personalities. In this episode, Shelly reveals commonly overlooked communication practices and advice on how we can get better at conveying our true selves. Tune in to learn secrets used by politicians and other communication experts.   3 KEY POINTS: Communication starts with building rapport. Good communication is being your true self and with open body language. Better communication leads to better outcomes.   EPISODE HIGHLIGHTS: Shelly went from politics to starting her own business in healthcare, helping companies influence the political arena. She got laid off and became burnt out applying for and working in several jobs before learning about Body Language and being certified. She struggled with communication and picked up bad habits growing up, so she devoted herself to improving later on. Politicians always deliver the message they want to convey quickly and clearly. Introverts tend to close themselves through body language. Try to open up your body language, keep your arms open, and make eye contact. To remember someone's name, associate their name with anything similar or write down bits of information about the person on a piece of paper when they leave the room. For social media, just be yourself and let the world see you, not being worried about perfecting what you post. In practicing your communication skills, start with small steps and with people you're comfortable with. Shelly recommends checking these people out: Vanessa Van Edwards - Behavioral Investigator at Science of People Joe Navarro - Former FBI Agent and Body Language Expert Dale Carnegie - Best-Selling “Author of How to Win Friends and Influence People” among other books   TWEETABLE QUOTES: “Authentic Influence means not trying to be somebody you're not. Just be yourself and let the world see you.” – Shelly O'Donovan “Open your body language more. Open your arms, make eye contact, and be curious about other people. Better communication leads to better outcomes.” – Shelly O'Donovan   CONNECT WITH JASON DUPRAT LinkedIn | Facebook | Instagram | Youtube Email: support@jasonduprat.com   ABOUT THE GUEST Shelly O'Donovan is the CEO of the Authentic Influence Group. She teaches Persuasive Speaking at the Wharton School, of the University of Pennsylvania. She has led vaccine advocacy for GSK, worked as a healthcare lobbyist, and served as a staffer in state government. She has been focused on cultivating authentic influence her entire career, and decoding what makes people tick. Shelly has an MPA from the University of Pennsylvania, a Marketing certification from Wharton School (of UPENN), and a BA in political science. She has a certification in body language training and the big 5 personalities from a behavioral research lab.   CONNECT WITH THE GUEST LinkedIn - https://www.linkedin.com/in/shellyodonovan/ Website - www.authenticinfluencegroup.com   RESOURCES Want to become a Ketamine Therapy provider? Enroll NOW in The Ketamine Academy course: ketamineacademy.com/presentation Have a healthcare business question? Want to request a podcast topic? Text me at 407-972-0084 and I'll add you to my contacts. Occasionally, I'll share important announcements and answer your questions as well. I'm excited to connect with you! Do you enjoy our podcast? Leave a rating and review: https://lovethepodcast.com/hea Don't want to miss an episode? Subscribe and follow: https://followthepodcast.com/hea   RELATED EPISODES: #198: TACTICAL TUESDAY: A GOLDEN OPPORTUNITY TO BUILD RELATIONSHIPS & CONVERT CUSTOMERS #229: TACTICAL TUESDAY: BRING OUT THE BEST IN YOURSELF & YOUR BUSINESS WITH A POSITIVE MINDSET #260: THE 5-STEP PRODUCTIVITY MUST-DO'S TO GET MORE OUT OF YOUR BUSINESS (MINUS THE BURNOUT!) WITH MRIDU PARIKH   #HealthcareEntrepreneurAcademy #healthcare #HealthcareBoss #entrepreneur #entrepreneurship #podcast #businessgrowth #teamgrowth #digitalbusiness

Rezidiv Therapie bekommt immer einen höheren Stellenwert in der Medizin. Mediziner, aber auch Sie als Angehörige und Patientinnen wissen, dass eine der Hauptsorgen bei einer Krebserkrankung ist: Kommt der Krebs wieder? Und wie wird das Rezidiv eigentlich erkannt? Deswegen wollen wir uns heute damit beschäftigen: Wie erkennt man das Rezidiv? Und was haben wir für therapeutische Möglichkeiten? Was bedeutet Immuntherapie? Ist es denn tatsächlich so, dass über die Nachsorge die meisten Rezidiv erkannt werden? Was sind was die wichtigsten und häufigsten Symptome, wie Luftnot, Schmerzen im Bein, Blutung, Nierenschmerzen, Ausfluss?Studien Portal: www.studienportal-gyn.deWebseite: https://www.krebs-podcast.deReferenten:Prof. Dr. med. Dr. h.c. Sehouli (Direktor der Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) und Klinik für Gynäkologie (CBF), Charité Berlin)Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin)Erfahren Sie in dieser von vier Folgen alles Rezidiv Therapie des Gebärmutterkörperkrebses. Erste Folgen zu der Serie Endometrium Karzinom: Folge 13-14. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten.In dieser Podcast-Episode wird über das Rezidiv von Gebärmutterkörperkrebs und die Möglichkeiten der Therapie gesprochen Nachsorge ist wichtig, sollte länger als 5 Jahre sein, und kann viele Jahre später auftreten. Trotz aller Vorsorge, können Tumoren in der Nachsorge wieder entdeckt werden. Daher sollten Patienten mit Beschwerden nicht erst auf den Termin in der Nachsorge warten, sondern das abklären lassen. Das Wichtigste ist, dass man daran denkt, nicht alle in Panik bringt, aber dann Schritt für Schritt nach untersucht. Die Diagnose eines Tumors erfolgt in der Regel durch eine Kombination aus verschiedenen Untersuchungsmethoden, Ultraschall, Computertomografie und Magnetresonanztomografie. Die Blutwerte sind nicht immer ausschlaggebend. Untersuchungen sollten nur bei Bedarf durchgeführt werden, um Schäden durch unnötige Röntgenstrahlung zu vermeiden. Die routinemäßige Verwendung von Computertomografie bei Patientinnen, die wegen eines Tumors operiert wurden, ist sinnlos. Die Ultraschalluntersuchung des Bauches und der und über die Scheide sollten Standard sein. Die Immuntherapie ist ein großes Thema, weil wir immer mehr lernen, dass das Immunsystem nicht nur die klassischen weißen Blutkörperchen sind, sondern alle Zellen, die letztlich mehr oder weniger das Immunsystem mit positiv beeinflussen, direkt und indirekt. Inzwischen kann man bei vielen Tumoren, inklusive Gebärmutterkörperkrebs, eine chemotherapiefreie Therapiestrategie anwenden. Immuntherapie ist eine neue Art der Krebstherapie, die das Immunsystem des Patienten gegen den Krebs richtet die auch in der Behandlung von Hautkrebs wie auch bei anderen Tumoren, inklusive Gebärmutterkörperkrebs eine Revolution ist. Es gibt verschiedene Arten der Immuntherapie, die für verschiedene Situationen zugelassen sind. Ob eine Person für eine bestimmte Art der Immuntherapie geeignet ist, hängt von verschiedenen Faktoren ab. Dazu sind Studien auch bei Ersttherapie im Gange. Hosted on Acast. See acast.com/privacy for more information.

The FDA has given Sarepta Therapeutics the green light for its phase 2 Duchenne muscular dystrophy clinical trial after slapping the biotech with a clinical hold in June. The hold came after a grade 3 adverse event was reported in the midstage trial. Now, only a few months later, the agency has lifted the hold, and we'll discuss why there was a quick turnaround on the hold and what to expect next.  To learn more about topics in this episode:  Sarepta picks up momentum as FDA lifts hold on phase 2 DMD trial  As EU challenge intensifies, Illumina clocks a stateside win in FTC antitrust case over Grail buy  EU blocks Illumina's yearslong quest for Grail  Philips recalls 17M CPAP and BiPAP machine masks due to potential magnet interference  GSK helps SpringWorks double payday from boosted combo deal as it also reels $225M in new funding  BMS-backed Arsenal Bio pulls trigger on $220M series B, touting potential fleet of gene-edited cell therapies  Amylyx's ALS drug faces tough FDA scrutiny ahead of 2nd advisory panel meeting The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Gebärmutterkörperkrebs kann einen sehr beunruhigenden und verwirrenden Zeitpunkt darstellen. Viele Patientinnen haben viele Fragen und wissen nicht, wo sie anfangen sollen. Patientinnen fragen sich oft, was sie selbst machen können, um die Behandlung zu unterstützen. Wie findet man eigentlich das richtige Zentrum? Wo finde ich Informationen über Studien zum Gebärmutterkörperkrebs. In dieser Podcastfolge möchten wir einige Tipps und Hinweise geben, worauf Sie vor und während einer Krebstherapie achten sollten. Dazu gehört zum Beispiel, sich über die verschiedenen Behandlungsmöglichkeiten zu informieren und herauszufinden, welche für Sie die Beste ist. Sie sollten auch einen Ernährungsplan erstellen, um sicherzustellen, dass Sie während der Behandlung ausreichend Nährstoffe zu sich nehmen. Alle Disziplinen in den Behandlungsplan einbeziehen. Studien Portal: www.studienportal-gyn.deWebseite: www.krebs-podcast.de Referenten:Prof. Dr. med. Dr. h.c. Jalid Sehouli (Direktorder Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) undKlinik für Gynäkologie (CBF), Charité Berlin)Dr. med. Robert Armbrust (Oberarzt, Klinik fürGynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin) Erfahren Sie in dieser von vier Folgen alles über alles über die Vorbereitung auf die Therapie des Gebärmutterkörperkrebses.Erste Folge der Gebähmutterkrebs-Serie über die neuesten Entwicklungen in der Diagnostik und Therapie des Gebärmutterkörperkrebses. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich.Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Original Air Date 3/16/2022 — Dr. Tania Small is the Vice President and Global Medical Oncology Head at GSK. She started her career as a pediatric oncologist and realized that her passion for helping patients would drastically accelerate by transitioning to the R&D side of healthcare. She did just that, as you'll hear in this episode when she describes how it felt to see her first FDA-approved medication prescribed to treat thousands more patients than she could have ever helped individually. Her latest passion is serving the GYN/ONC research community and sharing with Matthew the many new challenges and opportunities industry is tackling head-on to put the patient more at the center of care. Also, what role can women take in getting ahead of these diseases, and how can we collaborate to help patients survive and thrive? Also, what does she see as the most revolutionary biotech innovations on the horizon for women living with cancer? Medical progress can only do so much if patients have trouble accessing care, and Covid-19 has made us painfully aware of the racial and socioeconomic gaps in healthcare access. How do we break down those access barriers and help underserved communities get the services they need?For more information, visit https://OffScrip.com and follow @MatthewZachary, and @OffScripHealth on Twitter.This ad-free episode of Out of Patients is made possible by our partner, GlaxoSmithKline(GSK), a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer. For more information, please visit https://www.gsk.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Darnell Smith is the Founder and CEO of MXXN, a non-alcoholic, cannabis-infused spirits brand that is evolving today's cocktail culture and disrupting the alcohol and cannabis industry.  Darnell is A CPG and alcohol industry veteran and cannabis entrepreneur, innovator and advocate. Prior to founding MXXN and MOJO, Smith was a senior digital transformation lead at Infosys Consulting working with the likes of Adidas, Ralph Lauren, AB InBev, Novartis, GSK, Pfizer, AMEX and more. Prior to that, Smith worked for over a decade in various agency and client side roles focused on innovation and commercialization for the likes of Diageo and Pernod Ricard.

Jamie Schanbaum was a University of Texas student when she contracted meningitis in 2008. After two days in the hospital, Jamie was diagnosed with meningitis, and given only a twenty percent chance of survival. Jamie ultimately was faced with the difficult decision to amputate her lower legs and all fingers.Today, Jamie is a passionate advocate for vaccination for meningitis. In 2009, then-Texas Governor Rick Perry signed the Jamie Schanbaum Act, mandating meningitis vaccination for college students. With her mother, Jamie founded the J.A.M.I.E. Group (Joint Advocacy of Meningococcal Information & Education), supporting continued work toward meningitis prevention. In addition to her advocacy, Jamie is an accomplished cyclist, having competed with the U.S. Paralympic Cycling Team. Jamie works in sales and currently lives with her husband, Chris, and their dog, Billie Jean, in Austin, Texas. Dr. Iriny Salib  who is a vaccines researcher and educator, works at GSK as a Field Medical Liaison supporting vaccines. Passionate about immunizations, she uses her vast experience and medical knowledge to educate, inform  and simplify medical concepts. She works towards helping all individuals have access to CDC recommended vaccines and immunization information.  Dr. Salib earned her doctorate of pharmacy degree from Temple University in Philadelphia and has worked in various clinical pharmacy settings before coming to GSK in 2011. Learn more The J.A.M.I.E Group, - Ask2BSure Campaign- CDC Information on Meningitis B

Anthony Cross, co-manager of the popular Liontrust Special Situations fund, talks to Dave Baxter about the good and bad news coming out of his portfolio in this IC Interviews episode. This broad discussion covers the prospects of a variety of stocks and sectors, from challenges at Hargreaves Lansdown to the effect of recession worries on recruiters and property names, as well as an assessment of the slimmed-down GSK and a look at how rampant M&A activity has affected the fund. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

On Trending Health's third Trending News EU episode, Mindy, Jack, and Ollie discuss a few recent EU-based newsworthy items including: Haleon's demerger from GSK (0:58), a 'next generation' vaccine authorized by the UK in a world first (4:03), a sustainable medical device that will drastically reduce emissions (7.23), and the results from a survey ranking pharma companies in terms of their DE&I efforts (9.56).  Podcast Tags: healthcare, healthcare news, pharma, consumer health, vaccines, COVID-19, emissions, sustainability, DE&I, diversity, equity, inclusion  Source Links:  https://www.ft.com/content/45dc4b67-f4a5-4fac-8c35-1d63b823c065  https://www.gsk.com/en-gb/media/press-releases/gsk-introduces-haleon-to-investors/ https://www.telegraph.co.uk/news/2022/08/15/uk-authorises-next-generation-covid-omicron-booster-vaccine/  https://www.bbc.co.uk/news/health-62548336  https://www.washingtonpost.com/world/2020/12/08/uk-pfizer-biontech-vaccine-faq/  https://www.pharmatimes.com/news/chiesi_reinforces_commitment_to_reducing_emissions_1452746   https://pharmaphorum.com/news/bayer-tops-pharma-rankings-for-diversity-inclusivity/   For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.  Mindy McGrath, Executive and Healthcare Industry Advisor  mindy.mcgrath@vynamic.com  Jack Young, Director jack.young@vynamic.com  Oliver May, Manager  oliver.may@vynamic.com  

Self Awareness and Openness Builds Winning Teams What can we learn from the Special Forces to build workplace teams? Noel DiBona has served on high performance teams in private business and in military Special Operations.  Episode 109 (Noel is based in North Carolina) In this conversation with Noel DiBona we explore: How self awareness is the foundation for strong teams The importance of sharing strengths and blind spots Recognizing the effects of stress on you and your teammates Behavioral analysis and how to use it How not to forgo your perspective and authentic self When independence and collaboration clash About Noel DiBona: Noel began his career as an operations supervisor in a Clorox manufacturing facility and he was frustrated at the lack of productivity. He set out on a mission looking for ways to build better teams. Over 35 years he served on high-performing teams in military special operations and business. While serving in executive management at Fluor Corporate, CH2M and Tetra Tech he perfected a system to develop high-performing teams. As a consultant he has helped clients save millions of dollars through better resource use. His clients included Electrolux, DuPont, GSK and many others. Learn more about Noel DiBona and his services for building high-performing teams at the website www.ConsultDiBona.com You can arrange for a Team Improvement Plan (no charge) at the website. Excerpts from this conversation with Noel DiBona: 02:13 Delighted to be talking with you all. And I'm curious of all the teams you worked on, I would imagine working in Special Forces, one really learns how to appreciate all the nuances of a team working together for one purpose.   02:31 Absolutely George, in a team such as that high performance team, we all knew what our jobs were, we could fill in with for each other, we were cross trained, and were brutally honest with each other. But we would put our lives on the line for one another. So it was what you would consider to be the utmost highest respect, trust and open communication that you could possibly expect of any high performance team. It was truly a pleasure and an honor for me to be part of that through my career.   03:03 And Noel, did you find that you could take lessons learned in that team environment and apply it into business?   03:11 Absolutely, George, one of the things that we were able to do, when I came out of the military was really understand how people are orienting themselves towards getting their work done and how everybody works just a little bit differently. And when I came out of the military, I was very prone to looking forward to talking to people to understand what they were doing. And to just put myself in the learn mode. I was very inquisitive, asked lots of questions. I wanted to know how everything worked. And I got that from being in the military, because we're in contact with so many people, so many different folks from different walks of life, that I'm extremely comfortable dealing with many, many different types of individuals. And so right from the very beginning, when I got out of the military, I was focused on really building relationships with the people I worked with. ----- 06:52 In taking a deep dive into understanding ourself, and perhaps putting into words, features, characteristics that we never put into words, that's probably good for ourself. Is that also meant to be shared with the team saying, Hey, guys, here's how I think here's how I think through things. So please don't take it wrong when I do this?   07:18 Absolutely. The second part of this is for each individual on the team, to have an honest conversation with one another about their strengths, and their potential blind spots, the things that might make them a little bit not so easy to get along with when there's pressure and stress. We can talk with each other very openly, honestly, and in a cordial way, when there's no heat on us. But as the team comes under stress, the stress of everyday business, depending on what's happening in that company, people begin to work in a way where they might over utilize their strengths. And when they over utilize their strengths, there's a flipside to the good things that we do.  For example, we might be really proactive, and we might be independent minded, which is a really good thing when you're trying to bring change about in the organization. However, if the other people are more collaborative, and I'm under a lot of stress, then it's going to come across in a way that might not really be that good to build teamwork from it might tear down teamwork a little bit. So we want every individual to have an open and honest conversation with one another, in order to gain a better sense of appreciation of who we are. And we can do this with people that have worked with each other for years and years. And sometimes they know, obviously, a little bit more than if they had just started working with each other. But it's really, really interesting to note that in most cases, they learn things about people that they never knew. ----- That's what we want is a situational awareness, in terms of what we're doing, and how we might need to do something different in order to bring the results that we're after. ----more---- Your Intended Message is the podcast about how you can boost your career and business success by improving your communication skills. We'll examine the aspects of how we communicate one-to-one, one to few and one to many – plus that important conversation, one to self. In these interviews we will explore presentation skills, public speaking, conversation, persuasion, negotiation, sales conversations, marketing, team meetings, social media, branding, self talk and more.   Your host is George Torok George is a specialist in executive communication skills. That includes conversation and presentation. He's fascinated by way we communicate and influence behaviors. He delivers training and coaching programs to help leaders and promising professionals deliver the intended message for greater success.   Connect with George www.SpeechCoachforExecutives.com https://www.linkedin.com/in/georgetorokpresentations/ https://www.youtube.com/user/presentationskills https://www.instagram.com/georgetorok/   For weekly tips to improve your presentations visit https://toroktips.com/  

In this conversation from the MongoDB World Series event, Steve Westgarth speaks with MongoDB Principal Developer Advocate and host, Mike Lynn about his role at Haleon and how the company is leveraging MongoDB products, including Atlas. Haleon's mission is to empower everyday health, and while the company operates with a startup mentality, it was formerly part of GSK, and is a divestiture from the company.Conversation highlights: [01:46] Steve Westgarth of GSK, Haleon[02:58] MongoDB and GSK's relationship, implementation in Haleon[]05:38 Haleon as a divestiture and its startup mentality[06:40] Haleon's mission for everyday health[08:59] How Haleon will leverage MongoDB and Atlas[11:16] The great resignation and challenges facing engineering leaders[14:15] What Steve wants you to know about Haleon

Jenn speaks to Lydia Chang, founder of Origin Yoga & Wellness, Taiwan Lululemon legacy ambassador, and Wellness Director of Flow Retreat in Hualien, Taiwan. Lydia shares with us how her hyperthyroid diagnosis back in 2020 shocked her, made her feel like a failure as a wellness practitioner and her road to recovery. How she learned to heal from within and why self-love and self-compassion are so important to apply to our daily life.  (Recorded on March 14, 2022)About Lydia:Lydia came from a yoga family, and she started learning yoga and meditation from her father at the age of 10 years old. In 2016, Lydia took a leap of faith to leave behind her successful career in Canada as a corporate accountant, to start her own wellness retreat center in Taiwan. Since then, she focused on teaching and guiding personal wellness retreats and mindfulness workshops. Lydia has led over 300 group wellness retreats, and her clients include Google, PwC, GSK, Lululemon, and retreat guests from 50+ countries. This year, Lydia is invited to become Wellness Director of Flow Retreat in Hualien, Taiwan. Through Flow Retreat, Lydia is looking forward to expanding her retreat offerings to help more people discover balance in life.Episode Resources:WebsiteIGFBYoutubeReconciliation: Healing the Inner Child

Sunday, the U.S. Senate passed the landmark drug pricing bill. While the pharmaceutical industry favors the bill's Medicare out-of-pocket cap for patients, the industry has also put up a major fight against Medicare pricing negotiations, in fact deeming them "price controls." The bill's passage marked a loss for the industry, but analysts aren't sure how much the legislation will actually cut drug prices.  Pfizer is riding high on its COVID-19 windfall. And with all that money in the bank, the Big Pharma has been busy scouring the biopharma landscape for new assets and companies to bring into its fold. The latest in its buying spree is a $5.4 billion acquisition of Global Blood Therapeutics and its marketed sickle cell disease drug. To learn more about the topics in this episode:  Lilly, AZ, AbbVie and J&J face big potential hit from Medicare pricing bill: analysts 'Litany of false promises': Pharma bemoans drug pricing bill as patient advocates celebrate VC firms, biotechs push back on drug pricing bill that would render small molecule drugs 'uninvestable'  Pfizer, riding high on COVID windfall, strikes $5.4B buyout of Global Blood Therapeutics In historic FDA nod, AstraZeneca, Daiichi's Enhertu snags ultrafast approval in broad HER2-low breast cancer use  Struggling Novavax halves its sales forecast as COVID shot launch sputters Amid COVID vaccine demand slump, Moderna recorded $800M-plus in charges for unused inventory and more With COVID vaccine demand in free fall, BioNTech's revenue plummets nearly 40% in second quarter  GSK bets $1.3B on Mersana's preclinical ADC and chance to expand portfolio beyond Blenrep  Merck is back in Alzheimer's saddle with $1B+ Cerevance pact, years after dropping the BACE BMS bites at GentiBio's next-gen regulatory T cells, betting $1.9B on 3 programs In warranty program, Pfizer will refund up to $50K for patients who discontinue use of rare disease drug  We're looking for 2022's Fiercest Women in Life Sciences The Top Line is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

The recent U.S. equity rally stalls despite July wholesale prices showing a surprise decline. Treasury yields edge higher on anticipation the Federal Reserve can achieve a ‘Goldilocks' soft landing. In pharma news, GSK, Sanofi and Haleon all see shares slump due to continuing litigation issues relating to a recalled heartburn drug. UK GDP figures are due out with soaring utility prices set to weigh heavily. And U.S. EV maker Rivian posts a Q2 loss of $1.7bn, sending shares tumbling in after-hours trade. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

"The stock market outlook appears to be short covering. The stock market is headed for a recession if the Fed keeps tightening and inflation remains elevated. Investors will continue to see big risks until the Federal Reserve says risks have lessened. Berkshire Hathaway added $44B net in public equity this year," says James Locke. Locke provides his stock picks: CSCO, GSK, OKE, and OMC.

On today's episode Dr. Natanya Wachtel shares how understanding human behavior can close the gaps in customer communication and improve your brand message. Listen in as Deborah and Natanya discuss the importance of authenticity in branding, how to find weak links and make them stronger, and the role your team plays in identifying gaps and how to empower them to do more.   Innovative, tech-powered wellness solutions for chronic disease management at pharmaceutical companies, included launching some of the first, award-winning personalized CRM programs and earliest inclusions of behavioral psychology into pharmaceutical marketing. She is a featured speaker and mentor within her industry, and has been featured in the press including Forbes, Advertising Age and MM&M magazine.In 2008, Dr. Wachtel founded New Solutions Factory, a specialized consulting consortium of behavioral science marketing and healthcare analytics experts. In this position, she creatively partners with health and wellness brands to help them understand, manage and solve modern business challenges with a blend of customer-centric psychology, actionable behavioral models and technical innovation. Dr. Wachtel's expertise includes omnichannel customer engagement, branding, marketing, predictive analytics, customer relationship management, multi-channel and omnichannel ecosystem design, behavior modeling, market research and assessing behavioral-driven triggers.As the New Solutions Factory's founder and managing partner, Dr. Wachtel and her teams are responsible for leadi